Doximity (DOCS) is back in focus after extending its 13 year partnership with U.S. News & World Report, keeping its physician data and booking tools embedded in high traffic hospital rankings.
That renewed U.S. News agreement lands at a time when Doximity’s share price has swung sharply, with a 46.38% 90 day share price return and a 22.05% 30 day move, pointing to rebuilding momentum after a year to date share price decline of 27.23% and a 1 year total shareholder return fall of 53.22%.
Capture the rebound story around Doximity while scanning a curated set of healthcare peers with the 34 healthcare AI stocks.Doximity now trades slightly above the average analyst target yet screens at an intrinsic value discount. After such a sharp rebound, is the market still too cautious or already pricing in enough optimism?
Most Popular Narrative: 6.5% Undervalued
Doximity last closed at $31.50, while the most followed narrative on the stock pegs fair value at $33.70. This leaves a modest discount that keeps the rebound debate very much alive.
What I like about Doximity is that there really is a very high viewership / user base of active practicing Physicians in the US and that is not invaluable and definitely could be monetized perhaps more efficiently. I also think that Doximity offers a lot of interesting tools for Physicians a lot of which you’re free and really marketed towards I think Physicians who are more in private practice. It’s a little bit unclear how much value that provides given that most Physicians and practitioners these days are employed and not a private practice.
See why 10 investors see Doximity as 7% undervalued.
Result: Fair Value of $33.70 (UNDERVALUED)
Still, Doximity faces real pressure if hospital marketing budgets tighten or rival clinical AI platforms gain traction with the same high value physician audience.
Find out about the key risks to this Doximity narrative.
Another View: Doximity Through The P/E Lens
The SWS DCF model suggests Doximity trades at an 11.4% discount to fair value, yet the P/E story feels less patient. At 33.6x earnings versus a global healthcare services average of 28x and a fair ratio of 27x, buyers are paying up. Is that premium a margin of safety, or a margin of error?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment on Doximity is split, which is exactly when fresh eyes matter most. Move quickly, review the data yourself, and weigh both the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Doximity?
If Doximity has your attention, do not stop there. Use the same disciplined process to surface fresh opportunities before they move out of reach.
- Spot potential bargains early by scanning companies that combine quality fundamentals with attractive pricing through the 32 high quality undervalued stocks.
- Build a steadier income stream by reviewing businesses that feature resilient balance sheets and strong payouts using the 8 dividend fortresses.
- Reduce portfolio stress by focusing on companies that score well on resilience and risk using the 32 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com